<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735629</url>
  </required_header>
  <id_info>
    <org_study_id>CRTX-05</org_study_id>
    <nct_id>NCT02735629</nct_id>
  </id_info>
  <brief_title>Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia</brief_title>
  <official_title>Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RespireRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RespireRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an investigation to assess the capacity of ascending doses of CX1739 to
      antagonize the respiratory depressive effect of remifentanil. The study will also investigate
      whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the
      BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with
      remifentanil.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory depression</measure>
    <time_frame>Sequence #1 - 30 minutes</time_frame>
    <description>Respiratory rate, tidal volume, minute volume as determined by plethysmography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain tolerance threshold</measure>
    <time_frame>Sequence #2 - 20 minutes</time_frame>
    <description>Analgesia assessed by pain tolerance threshold to 5, 250, and 2000 Hertz sine-wave electrical stimulation using the quantitative sensory testing device - Neurometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of sedation</measure>
    <time_frame>Sequence #1 - 30 minutes</time_frame>
    <description>Bispectral index (BIS) measure of sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients that experience an adverse drug reaction upon ingestion of CX1739 when used alone or in conjunction with remifentanil</measure>
    <time_frame>up to 5 weeks</time_frame>
    <description>Vital signs, including noninvasive blood pressure, heart rate, RR, end-tidal carbon dioxide, pulse oximetry saturation, and temperature
Electrocardiograms
Focused physical examinations
Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pupil size</measure>
    <time_frame>Sequence #2 - 20 minutes</time_frame>
    <description>Pupil size will be assessed intermittently with a noninvasive pupillometer incorporated into a pair of glasses placed on the subject's head</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Opiate Induced Respiratory Depression</condition>
  <arm_group>
    <arm_group_label>CX1739 - 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug - low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX1739 - 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug - mid Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX1739 - 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug - high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX1739 - 300 mg</intervention_name>
    <description>Ampakine CX1739 - 300 mg</description>
    <arm_group_label>CX1739 - 300 mg</arm_group_label>
    <other_name>Low dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX1739 - 600 mg</intervention_name>
    <description>CX1739 - 600 mg</description>
    <arm_group_label>CX1739 - 600 mg</arm_group_label>
    <other_name>mid dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX1739 - 900 mg</intervention_name>
    <description>CX1739 - 900 mg</description>
    <arm_group_label>CX1739 - 900 mg</arm_group_label>
    <other_name>high dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to 300 mg CX1739</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo to 300 mg CX1739</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible for this trial, subjects must meet all of the following criteria:

               1. Males 18 to 50 years of age, inclusive

               2. Body mass index of 18.0 to 30.0 kg/m2, inclusive, using the formula: weight
                  (kg)/height (m)2

               3. Healthy, as determined by medical history, physical examination including vital
                  signs, and clinical laboratory test results

               4. American Society of Anesthesiologists Physical Status Classification 1

               5. Willing and able to provide voluntary, written informed consent

        Exclusion Criteria:

          -  If a subject meets any of the following criteria, he cannot be enrolled in the study:

               1. History of any chronic illness or evidence of clinically significant organic or
                  psychiatric disease on medical history or physical examination which, in the
                  opinion of the principal investigator (PI), would confound the study results or
                  present a risk to the subject

               2. Acute illness within 2 weeks before dosing

               3. History of any clinically significant pulmonary condition (eg, asthma) within the
                  last 2 years requiring admission to the hospital

               4. Previous diagnosis of obstructive sleep apnea based on polysomnography

               5. Currently using any prescription medication or use within the last 30 days

               6. Laboratory values (clinical chemistry, hematology, urinalysis) outside the
                  laboratory reference range considered clinically significant (NOTE: in the event
                  of any parameter lying outside of the normal range, the sample may be repeated
                  once; this value will be accepted if it lies within the normal range)

               7. Presence of QT interval corrected &gt; 440 msec on ECG

               8. Resting HR while awake &lt; 45 or &gt; 90 beats/minute

               9. History of daily use of tobacco or other nicotine-containing products within 1
                  year of study entry or positive cotinine test at screening and subsequent study
                  visits

              10. History of allergic hypersensitivity to ampakines (CX717, CX1739), remifentanil,
                  naloxone, or any component of these formulations; history of multiple drug
                  allergies

              11. History or current evidence of abuse of any drug substance, licit or illicit,
                  including alcohol; positive urine drug screen (UDS) for drugs of abuse at
                  screening

              12. Inability to understand the protocol requirements; instructions; study-related
                  restrictions; or nature, scope, and possible consequences of the study

              13. Unlikely to complete the study, eg, because of inability to return for follow-up
                  visits

              14. Participation in another study with any investigational drug in the 3 months
                  preceding this study

              15. Blood or plasma donation of more than 500 mL during the month before
                  randomization and more than 50 mL in the 2 weeks before randomization
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Purcell</last_name>
    <role>Study Director</role>
    <affiliation>RespireRx Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 9, 2017</submitted>
    <returned>November 9, 2017</returned>
    <submitted>December 7, 2017</submitted>
    <returned>January 9, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

